Valeant Pharmaceuticals International Inc (VRX)

23.36
0.31 1.30
NYSE : Health Care
Prev Close 23.05
Open 23.14
Day Low/High 23.06 / 23.38
52 Wk Low/High 18.55 / 263.81
Volume 1.32M
Avg Volume 31.54M
Exchange NYSE
Shares Outstanding 343.03M
Market Cap 7.84B
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Valeant Slides as FDA Report Hampers Drug Application

Valeant Slides as FDA Report Hampers Drug Application

Valeant's pipeline drug has so far failed to pass FDA muster following a manufacturing plant inspection.

Valeant (VRX) Stock Down on Concerns About Glaucoma Treatment

Valeant (VRX) Stock Down on Concerns About Glaucoma Treatment

Valeant (VRX) stock is lower this morning after the FDA decided against approving its glaucoma treatment.

Valeant Drug Approval Hampered by FDA Facility Inspection

Valeant Drug Approval Hampered by FDA Facility Inspection

The beleaguered drugmaker says the FDA raised red flags at a Tampa-based manufacturing plant.

Here Are Some Small-Cap Pharma M&A Targets After Relypsa Deal

Here Are Some Small-Cap Pharma M&A Targets After Relypsa Deal

Investors may want to look at some small-cap pharma names that could be takeover targets like Relypsa.

Investors Scour Big Pharma M&A Scene for Next Big Takeover

Investors Scour Big Pharma M&A Scene for Next Big Takeover

Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.

4 Small-Cap Biotechs With Big Stories to Tell

4 Small-Cap Biotechs With Big Stories to Tell

Watch these names as stability returns to the sector.

Dow Closes at Record High for 7th Straight Session as Microsoft Surges

Dow Closes at Record High for 7th Straight Session as Microsoft Surges

The Dow Jones Industrial Average clocks its seventh straight record closing Wednesday amid better-than-expected earnings from Microsoft, the best performing stock in the blue-chip index.

These 3 Stocks Are Rising on Big Volume -- Is It Time to Buy?

These 3 Stocks Are Rising on Big Volume -- Is It Time to Buy?

Here's a look at how to trade some of the most active stocks on the market right now.

S&P 500, Dow on Track to Break Records as Microsoft Surges

S&P 500, Dow on Track to Break Records as Microsoft Surges

Stocks are at record intraday highs by mid-afternoon Wednesday as crude oil trades above $45 and positive quarterly results for Microsoft spread earnings season cheer.

Here's Why Jim Cramer Is Positive About Valeant Pharmaceuticals

Here's Why Jim Cramer Is Positive About Valeant Pharmaceuticals

Jim Cramer was encouraged by the slew of drug approvals Valeant Pharmaceuticals received from the FDA.

Midday Report: Valeant Jumps on FDA Approval; Dow at Records

Midday Report: Valeant Jumps on FDA Approval; Dow at Records

Stocks moved higher, boosted by a series of earnings reports from the likes of Microsoft, Morgan Stanley and United Continental.

Valeant's Drug Approvals May Save the Day

Valeant's Drug Approvals May Save the Day

Valeant could rake in more than $1 billion annually in new sales after FDA approval of a key drug.

Stocks Move Higher as Crude Pares Losses

Stocks Move Higher as Crude Pares Losses

Stocks move higher on Wednesday after a weekly reading on crude oil inventories confirms declining supplies.

Jim Cramer -- Valeant Needs These New Drug Approvals

Jim Cramer -- Valeant Needs These New Drug Approvals

Valeant received preliminary drug approvals, which has drawn the approval of stock buyers, Cramer says.

Valeant (VRX) Stock Gains as FDA Approves Anticonstipation Drug

Valeant (VRX) Stock Gains as FDA Approves Anticonstipation Drug

Valeant (VRX) stock is trading higher after the FDA approved its drug to treat constipation shortly after an FDA advisory board backed its psoriasis treatment.

Valeant Scores 'Vindicating Win' as 2 Key Drugs Clear FDA Hurdles

Valeant Scores 'Vindicating Win' as 2 Key Drugs Clear FDA Hurdles

Valeant could rake in more than $1 billion annually in new sales after FDA approval of a key drug.

Dow on Track for Another Record Open as Microsoft Surges

Dow on Track for Another Record Open as Microsoft Surges

Stock futures climb on Wednesday as better-than-expected earnings from Microsoft push the stock higher in premarket trading.

Morning Movers: MS, VRX, MSFT, ISRG

Morning Movers: MS, VRX, MSFT, ISRG

Morgan Stanley surprised Wall Street with $600 million more in revenue than expected on the quarter.

Futures Point Downward for U.S. Markets as Asia Opens Lower

Futures Point Downward for U.S. Markets as Asia Opens Lower

Investors are beginning to wonder if earnings season can support the latest records.

Trade-Ideas: Valeant Pharmaceuticals International (VRX) Is Today's Post-Market Leader Stock

Trade-Ideas: Valeant Pharmaceuticals International (VRX) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified Valeant Pharmaceuticals International (VRX) as a post-market leader candidate

Valeant And Progenics Announce FDA Approves RELISTOR® Tablets For The Treatment Of Opioid-Induced Constipation In Adults With Chronic Non-cancer Pain

Valeant And Progenics Announce FDA Approves RELISTOR® Tablets For The Treatment Of Opioid-Induced Constipation In Adults With Chronic Non-cancer Pain

Sales of RELISTOR tablets are expected to commence in the Third Quarter 2016

New Valeant (VRX) Drug Gains Approval From FDA Panel

New Valeant (VRX) Drug Gains Approval From FDA Panel

The FDA's outside advisory committee has approved Valeant's (VRX) new drug for psoriasis.

Valeant (VRX) Stock Higher, FDA Panel Backs Psoriasis Drug

Valeant (VRX) Stock Higher, FDA Panel Backs Psoriasis Drug

Valeant (VRX) stock is advancing as an FDA advisory panel backed its psoriasis drug with risk management measures.

Netflix Shares Plummet as Subscriber Growth Disappoints Investors

Netflix Shares Plummet as Subscriber Growth Disappoints Investors

Netflix shares fell as much as 12% overnight after it added far fewer subscribers than expected.

Valeant Stock Surges Ahead of Anticipated Drug Approval

Valeant Stock Surges Ahead of Anticipated Drug Approval

Shares of the Valeant Pharmaceuticals were higher Monday on word the Food and Drug Administration could decide Tuesday on the new drug application of Relistor Oral.

Valeant Partnership With Walgreens in Trouble: Andrew Left

Valeant Partnership With Walgreens in Trouble: Andrew Left

The Canadian drugmaker could again be hit by its unprofitable Walgreens deal as earnings loom.